What is infectious mononucleosis?
What causes infectious mononucleosis?
Who gets infectious mononucleosis?
How does EBV cause disease?
What are the common findings?
How is infectious mononucleosis diagnosed?
How is infectious mononucleosis treated?
What are the complications?
How can infectious mononucleosis be prevented?
What research is being done?
by Hal B. Jenson, M.D.
Chief, Pediatric Infectious Diseases
University of Texas Health Science Center
San Antonio, TX
by Charles T. Leach, M.D.
Associate Professor of Pediatrics
University of Texas Health Science Center
San Antonio, TX
Infectious mononucleosis, also known as "kissing disease," mononucleosis, or, sometimes,
just "mono," is an illness characterized by many complaints, but primarily by fever,
fatigue, tiredness, enlarged lymph nodes ("lymphadenopathy"), and a sore throat.
This disease was originally described in the late nineteenth century as "glandular
fever," and it is still known by that name in Europe.
The Epstein-Barr Virus (EBV), a DNA virus that is a member of the herpesvirus family
of viruses, causes approximately 90% of cases of infectious mononucleosis. Approximately
10% of cases of infectious mononucleosis-like illnesses are caused by primary infection
with cytomegalovirus, Toxoplasma gondii, Human Immunodeficiency Virus (HIV), adenovirus,
viral hepatitis, and rubella virus.
EBV is found throughout the world and infects more than 98% of the world's population.
In underdeveloped and developing countries, and in socio-economically disadvantaged
populations of the United States, up to 100% of children are infected with EBV by
2 to 4 years of age. In more affluent populations in the United States, initial
EBV infection also occurs more often in young children, but approximately 50% of
infection occurs during adolescence and young adulthood. Because initial EBV infection
in young children tends to be without any symptoms, most cases of what is diagnosed
as infectious mononucleosis occurs in adolescence and young adulthood, even though
EBV infection is more common in young children.
EBV and the other causes of infectious mononucleosis are transmitted from person-to-person
by direct contact or by contaminated secretions of the nose and the mouth. EBV then
causes infection in the throat that results in the symptoms of a sore throat and
swollen lymph nodes in the neck. The virus then spreads to the white blood cells
in the blood stream and causes enlarged lymph nodes in other places throughout the
body. The virus, like all other herpesviruses, establishes lifelong infection in
the affected person. However, this lifelong infection generally does not cause any
six weeks. Initial infection in young children is often without any symptoms, or
with only mild symptoms. Primary infection in approximately 50% of adolescents and
adults appears as fever, fatigue and tiredness, swollen lymph nodes, a sore throat,
and, sometimes, an enlarged spleen and liver. Symptoms typically develop over several
days and persist for a variable period of days, with gradual spontaneous resolution.
The total duration of the disease usually is two to three weeks without complications.
Initially, infectious mononucleosis can be diagnosed in an adolescent or adult on
the basis of the typical symptoms-fever, fatigue and malaise, swollen lymph nodes,
and a sore throat. The complete blood count may show an uncommon type of white blood
cells ("atypical lymphocytes"), which can suggest infectious mononucleosis. The
diagnosis is confirmed by checking for antibodies to the virus. If one of the many
other causes of infectious mononucleosis is considered, specific blood tests for
those causes are available.
There is no specific treatment for infectious mononucleosis. Antibiotics usually
are not helpful because the primary cause, EBV, is a virus. Viruses cannot be treated
with antibiotics. Antiviral therapy with acyclovir has been shown to decrease viral
growth and shedding of EBV from the mouth, but this treatment does not affect the
severity of symptoms, the duration of the clinical course, or the eventual outcome.
Infectious mononucleosis is treated primarily with rest and symptomatic therapy.
Fever should be treated with acetaminophen or ibuprofen. Because the spleen may
be enlarged and may easily rupture, it is advisable to refrain from participation
in any contact sports and strenuous physical activities for the first two to three
weeks of illness, or, if an enlarged spleen is present, until it has resolved.
Some patients with infectious mononucleosis have such greatly enlarged tonsils that
they have difficulty breathing or swallowing. For these patients, steroids have
been shown to have a dramatic effect in shrinking enlarged tonsils within 12 to
24 hours. However, most persons with infectious mononucleosis do not require steroids.
The great majority of patients with infectious mononucleosis recover uneventfully
without complications. Some chronic conditions have been suggested to be associated
with infectious mononucleosis, but this has not been proved. At present, there is
no evidence to support the association of EBV infection with chronic fatigue syndrome
or chronic immune dysfunction.
EBV is a virus that has been associated with several human cancers, including nasopharyngeal
carcinoma, Burkitt lymphoma, Hodgkin disease, and lymphomas and smooth muscle tumors
("leiomyosarcomas") in individuals with decreased ability to ward off other infections.
There is no vaccine for EBV or the other causes of infectious mononucleosis. There
is very little information on how to prevent it. Outbreaks are uncommon. Minimizing
exposure to the oral secretions of infected persons can prevent the spread of infectious
mononucleosis. Most healthy adults excrete EBV from the mouth periodically throughout
their lives, with approximately 20% of the healthy adult population excreting EBV
at any given time.
There is much research into the molecular events that are important in the control
of EBV after the initial infection resolves. There is interest in developing a vaccine
because almost everybody is infected with EBV in childhood and because of the association
of EBV with several types of cancer.
About the Authors
Hal Jenson, M.D.
Dr. Jenson graduated from George Washington University School of Medicine in Washington,
He also completed a residency in pediatrics at the Rainbow Babies and Children's
Hospital of Case Western Reserve University in Cleveland, Ohio, and a fellowship
in pediatric infectious diseases and epidemiology at Yale University School of Medicine.
Dr. Jenson has an active research program on the biology of Epstein-Barr virus and
other human and non-human primate herpes viruses.
He is active in the general pediatric and infectious diseases teaching and clinical
activities of his Department and Division, is a co-editor of Nelson Textbook of
Pediatrics and of Pediatric Infectious Diseases: Principles and Practice, and authors
the book Pocket Guide to Vaccination and Prophylaxis.
Charles T. Leach, M.D.
Dr. Leach received his medical degree at the University of Utah School of Medicine
and completed his pediatrics residency as well as a fellowship in pediatric infectious
diseases at UCLA.
He is currently Associate Professor and Director of Research in the Department of
Pediatrics at the University of Texas Health Science Center at San Antonio.
Dr. Leach conducts scientific research in the areas of herpes virus infections,
pediatric AIDS, and infectious diseases among residents of the Texas-Mexico border.
Copyright 2012 Hal B. Jenson, M.D., All Rights Reserved